Lisata Acquires Marea Therapeutics with $225M Private Placement
LSTA sits 49% above its 52-week low of $0.988 on light trading volume (0.4× avg).
Summary
Lisata Therapeutics is acquiring Marea Therapeutics and raising $225 million in a concurrent private placement. This is a transformative deal for a company that recently terminated its merger with Kuva Labs and cut 72% of its workforce. The acquisition brings new assets and the financing provides runway. The $225 million raise is highly dilutive given Lisata's $13 million market cap, but it signals investor confidence in the new direction. Watch for details on Marea's pipeline and the terms of the private placement.
At the time of this announcement, LSTA was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.99 to $5.07. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.